Development of human-derived, three-dimensional respiratory epithelial tissue constructs with perfusable microvasculature on a high-throughput microfluidics screening platform.
Development of human-derived, three-dimensional respiratory epithelial tissue constructs with perfusable microvasculature on a high-throughput microfluidics screening platform.
复制标题
DOI:
10.1088/1758-5090/ac32a5
复制
发表时间:
2022-02-14
期刊:
影响因子:
9
通讯作者:
中科院分区:
文献类型:
--
作者:
The COVID-19 pandemic has highlighted the need for human respiratory tract-based assay platforms for efficient discovery and development of antivirals and disease-modulating therapeutics. Physiologically relevant tissue models of the lower respiratory tract, including the respiratory bronchioles and the alveolar sacs, are of high interest because they are the primary site of severe SARS-CoV-2 infection and are most affected during the terminal stage of COVID-19. Current epithelial lung models used to study respiratory viral infections include lung epithelial cells at the air-liquid interface with fibroblasts and endothelial cells, but such models do not have a perfusable microvascular network to investigate both viral infectivity and viral infection-induced thrombotic events. Using a high throughput, 64-chip microfluidic plate-based platform, we have developed two novel vascularized, lower respiratory tract multi-chip models for the alveoli and the small airway. Both models include a perfusable microvascular network consisting of human primary microvascular endothelial cells, fibroblasts and pericytes. The established biofabrication protocols also enable the formation of differentiated lung epithelial layers at the air-liquid interface on top of the vascularized tissue bed. We validated the physiologically relevant cellular composition, architecture and perfusion of the vascularized lung tissue models using fluorescence microscopy, flow cytometry, and electrical resistance measurements. These vascularized, perfusable microfluidic lung tissue on high throughput assay platforms will enable the development of respiratory viral infection and disease models for research investigation and drug discovery.
登录
查看更多内容
DOI:
10.1016/j.ejpb.2010.10.014
发表时间:
2011-04-01
影响因子:
4.9
作者:
Lehmann, Andrea D.;Daum, Nicole;Rothen-Rutishauser, Barbara M.
通讯作者:
Rothen-Rutishauser, Barbara M.
影响因子:
4.6
作者:
Chen F;Zhang Y;Sucgang R;Ramani S;Corry D;Kheradmand F;Creighton CJ
通讯作者:
Creighton CJ
影响因子:
4.6
作者:
Cozens D;Grahame E;Sutherland E;Taylor G;Berry CC;Davies RL
通讯作者:
Davies RL
DOI:
10.1073/pnas.1434429100
发表时间:
2003-09-16
影响因子:
11.1
作者:
Chi, JT;Chang, HY;Brown, PO
通讯作者:
Brown, PO
影响因子:
17.1
作者:
Barosova, Hana;Maione, Anna G.;Rothen-Rutishauser, Barbara
通讯作者:
Rothen-Rutishauser, Barbara